| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 96 | 2024 | 1776 | 14.630 |
Why?
|
| Brain Neoplasms | 117 | 2024 | 4966 | 11.480 |
Why?
|
| Glioma | 46 | 2024 | 1986 | 5.720 |
Why?
|
| Angiogenesis Inhibitors | 22 | 2023 | 1270 | 4.180 |
Why?
|
| Bevacizumab | 22 | 2020 | 967 | 3.080 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 10 | 2017 | 361 | 1.700 |
Why?
|
| Oligodendroglioma | 7 | 2022 | 105 | 1.650 |
Why?
|
| Isocitrate Dehydrogenase | 12 | 2023 | 522 | 1.610 |
Why?
|
| Vascular Endothelial Growth Factor A | 12 | 2017 | 1580 | 1.510 |
Why?
|
| Astrocytoma | 6 | 2022 | 325 | 1.480 |
Why?
|
| Antineoplastic Agents, Alkylating | 7 | 2021 | 605 | 1.480 |
Why?
|
| Dacarbazine | 10 | 2021 | 502 | 1.460 |
Why?
|
| Neoplasm Recurrence, Local | 25 | 2024 | 10400 | 1.450 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2020 | 5417 | 1.450 |
Why?
|
| Antineoplastic Agents | 27 | 2024 | 14636 | 1.380 |
Why?
|
| Clinical Trials as Topic | 16 | 2024 | 3846 | 1.360 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2021 | 125 | 1.290 |
Why?
|
| Lomustine | 6 | 2023 | 42 | 1.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 14 | 2020 | 3416 | 1.120 |
Why?
|
| Immunotherapy | 7 | 2024 | 3559 | 1.100 |
Why?
|
| Humans | 175 | 2024 | 271093 | 1.080 |
Why?
|
| Recombinant Fusion Proteins | 7 | 2017 | 1630 | 1.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2024 | 235 | 0.850 |
Why?
|
| Neovascularization, Pathologic | 7 | 2016 | 1586 | 0.810 |
Why?
|
| Biomarkers, Tumor | 19 | 2022 | 10714 | 0.750 |
Why?
|
| Neurofibromatosis 1 | 3 | 2022 | 159 | 0.740 |
Why?
|
| Gliosarcoma | 2 | 2022 | 32 | 0.710 |
Why?
|
| Encephalitis, Viral | 1 | 2020 | 29 | 0.700 |
Why?
|
| Xenograft Model Antitumor Assays | 16 | 2021 | 3924 | 0.700 |
Why?
|
| Meningeal Neoplasms | 4 | 2023 | 473 | 0.700 |
Why?
|
| Receptors, AMPA | 3 | 2010 | 82 | 0.680 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2017 | 561 | 0.670 |
Why?
|
| Headache | 1 | 2020 | 175 | 0.660 |
Why?
|
| Molecular Biology | 2 | 2012 | 179 | 0.660 |
Why?
|
| Neoplasm Proteins | 3 | 2017 | 3345 | 0.660 |
Why?
|
| Immunologic Factors | 2 | 2021 | 670 | 0.650 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 103 | 0.650 |
Why?
|
| Cranial Irradiation | 3 | 2020 | 321 | 0.630 |
Why?
|
| Blood-Brain Barrier | 5 | 2024 | 251 | 0.610 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2019 | 1095 | 0.610 |
Why?
|
| Autophagy | 3 | 2015 | 906 | 0.600 |
Why?
|
| Myeloid Cells | 4 | 2019 | 272 | 0.600 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2020 | 551 | 0.600 |
Why?
|
| Mice, Nude | 13 | 2019 | 4331 | 0.590 |
Why?
|
| Therapies, Investigational | 1 | 2018 | 60 | 0.580 |
Why?
|
| Brain Diseases | 2 | 2020 | 411 | 0.580 |
Why?
|
| Research Design | 4 | 2023 | 1570 | 0.580 |
Why?
|
| Prognosis | 20 | 2020 | 22529 | 0.580 |
Why?
|
| Neoplasm Grading | 9 | 2021 | 1824 | 0.570 |
Why?
|
| Cell Adhesion Molecules | 2 | 2018 | 564 | 0.560 |
Why?
|
| Meningioma | 4 | 2023 | 308 | 0.560 |
Why?
|
| Neoplasms | 11 | 2023 | 15933 | 0.560 |
Why?
|
| Isotretinoin | 3 | 2014 | 161 | 0.560 |
Why?
|
| Adult | 56 | 2024 | 82174 | 0.560 |
Why?
|
| S100 Proteins | 2 | 2015 | 184 | 0.550 |
Why?
|
| Female | 75 | 2024 | 149120 | 0.540 |
Why?
|
| Cell Line, Tumor | 22 | 2021 | 14873 | 0.540 |
Why?
|
| Tumor Microenvironment | 7 | 2024 | 3041 | 0.540 |
Why?
|
| Mutation | 19 | 2024 | 15904 | 0.530 |
Why?
|
| Middle Aged | 58 | 2024 | 90524 | 0.530 |
Why?
|
| Drug Delivery Systems | 2 | 2024 | 662 | 0.530 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 376 | 0.530 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2016 | 108 | 0.520 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 204 | 0.520 |
Why?
|
| Precision Medicine | 5 | 2021 | 1210 | 0.520 |
Why?
|
| Procarbazine | 1 | 2015 | 71 | 0.520 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2015 | 54 | 0.510 |
Why?
|
| Animals | 38 | 2024 | 61554 | 0.510 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2016 | 198 | 0.510 |
Why?
|
| Neutrophils | 1 | 2020 | 855 | 0.500 |
Why?
|
| Thiazoles | 3 | 2010 | 727 | 0.500 |
Why?
|
| Male | 68 | 2024 | 128484 | 0.490 |
Why?
|
| Injections, Intraventricular | 1 | 2014 | 124 | 0.490 |
Why?
|
| Neurology | 2 | 2024 | 120 | 0.480 |
Why?
|
| Aged | 42 | 2024 | 73550 | 0.470 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2023 | 7900 | 0.470 |
Why?
|
| Seizures | 1 | 2020 | 997 | 0.470 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2020 | 6258 | 0.470 |
Why?
|
| Glutamic Acid | 2 | 2010 | 335 | 0.470 |
Why?
|
| Molecular Targeted Therapy | 6 | 2021 | 2395 | 0.460 |
Why?
|
| Topotecan | 1 | 2014 | 248 | 0.460 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2018 | 4965 | 0.460 |
Why?
|
| Neurosurgical Procedures | 3 | 2019 | 634 | 0.450 |
Why?
|
| Brain | 7 | 2021 | 4205 | 0.450 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 658 | 0.450 |
Why?
|
| Ganglioglioma | 1 | 2013 | 40 | 0.440 |
Why?
|
| Models, Biological | 5 | 2017 | 3189 | 0.440 |
Why?
|
| Stem Cells | 3 | 2017 | 1213 | 0.430 |
Why?
|
| Cysts | 1 | 2014 | 206 | 0.430 |
Why?
|
| Cell Proliferation | 14 | 2017 | 7232 | 0.430 |
Why?
|
| Survival Analysis | 13 | 2019 | 9290 | 0.420 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2019 | 2359 | 0.420 |
Why?
|
| Brain Stem Neoplasms | 2 | 2015 | 100 | 0.420 |
Why?
|
| Signal Transduction | 12 | 2017 | 12044 | 0.420 |
Why?
|
| Pyrimidines | 6 | 2024 | 3671 | 0.410 |
Why?
|
| Mice | 23 | 2021 | 35477 | 0.410 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 626 | 0.410 |
Why?
|
| Anilides | 4 | 2018 | 295 | 0.410 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2019 | 4006 | 0.410 |
Why?
|
| Disease-Free Survival | 16 | 2020 | 10267 | 0.410 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2013 | 246 | 0.410 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 703 | 0.410 |
Why?
|
| Treatment Outcome | 23 | 2023 | 33808 | 0.400 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 4104 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 4481 | 0.400 |
Why?
|
| Macrophages | 5 | 2020 | 1333 | 0.400 |
Why?
|
| Retrospective Studies | 23 | 2023 | 39951 | 0.400 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2012 | 98 | 0.390 |
Why?
|
| Neoplasm Invasiveness | 6 | 2016 | 4052 | 0.380 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2024 | 1852 | 0.370 |
Why?
|
| Genomics | 4 | 2018 | 2832 | 0.370 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2017 | 1008 | 0.370 |
Why?
|
| Karnofsky Performance Status | 3 | 2019 | 174 | 0.370 |
Why?
|
| Cerebellar Neoplasms | 2 | 2013 | 475 | 0.360 |
Why?
|
| Medulloblastoma | 2 | 2013 | 569 | 0.350 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2012 | 334 | 0.350 |
Why?
|
| Proteomics | 1 | 2017 | 1425 | 0.350 |
Why?
|
| Combined Modality Therapy | 9 | 2024 | 9039 | 0.350 |
Why?
|
| src-Family Kinases | 2 | 2010 | 487 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2024 | 16720 | 0.340 |
Why?
|
| Young Adult | 23 | 2024 | 22293 | 0.330 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2019 | 2050 | 0.330 |
Why?
|
| Dapsone | 1 | 2009 | 15 | 0.330 |
Why?
|
| Methemoglobinemia | 1 | 2009 | 17 | 0.330 |
Why?
|
| Wernicke Encephalopathy | 1 | 2008 | 12 | 0.320 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 1837 | 0.310 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2016 | 266 | 0.300 |
Why?
|
| Integrin beta1 | 1 | 2008 | 127 | 0.300 |
Why?
|
| Pyridines | 4 | 2018 | 1313 | 0.300 |
Why?
|
| Cytokines | 3 | 2017 | 2805 | 0.290 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 1002 | 0.290 |
Why?
|
| Cell Hypoxia | 3 | 2013 | 353 | 0.290 |
Why?
|
| Extracellular Matrix | 3 | 2008 | 523 | 0.290 |
Why?
|
| Age Factors | 5 | 2020 | 5458 | 0.280 |
Why?
|
| Medical Oncology | 3 | 2023 | 1463 | 0.280 |
Why?
|
| Drug Therapy | 1 | 2007 | 205 | 0.280 |
Why?
|
| Camptothecin | 2 | 2008 | 540 | 0.270 |
Why?
|
| Disease Progression | 9 | 2019 | 6868 | 0.270 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2022 | 637 | 0.270 |
Why?
|
| Quinazolines | 6 | 2017 | 956 | 0.260 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5581 | 0.260 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 1132 | 0.260 |
Why?
|
| Cell Cycle | 5 | 2017 | 2135 | 0.260 |
Why?
|
| DNA Damage | 3 | 2024 | 1990 | 0.260 |
Why?
|
| Molecular Imaging | 2 | 2018 | 186 | 0.260 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 1338 | 0.260 |
Why?
|
| Aminopyridines | 2 | 2019 | 223 | 0.250 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2005 | 26 | 0.250 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 466 | 0.240 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2022 | 529 | 0.240 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2018 | 694 | 0.240 |
Why?
|
| Recurrence | 6 | 2019 | 4880 | 0.240 |
Why?
|
| Patient Selection | 3 | 2019 | 2032 | 0.230 |
Why?
|
| Quality of Life | 1 | 2018 | 4794 | 0.230 |
Why?
|
| RNA Interference | 1 | 2008 | 1379 | 0.230 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 898 | 0.220 |
Why?
|
| Immunohistochemistry | 6 | 2017 | 7645 | 0.220 |
Why?
|
| Survival Rate | 11 | 2020 | 12535 | 0.220 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 503 | 0.220 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 12040 | 0.220 |
Why?
|
| Apoptosis | 5 | 2016 | 7755 | 0.220 |
Why?
|
| Vestibule, Labyrinth | 1 | 2023 | 44 | 0.210 |
Why?
|
| Patient Care Team | 2 | 2024 | 823 | 0.210 |
Why?
|
| Gene Expression | 3 | 2018 | 3606 | 0.210 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2019 | 1704 | 0.200 |
Why?
|
| Cohort Studies | 7 | 2019 | 9479 | 0.200 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 2189 | 0.200 |
Why?
|
| Blotting, Western | 4 | 2015 | 3570 | 0.200 |
Why?
|
| Thalidomide | 4 | 2014 | 597 | 0.200 |
Why?
|
| Endpoint Determination | 3 | 2018 | 180 | 0.200 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2024 | 573 | 0.190 |
Why?
|
| Contrast Media | 2 | 2018 | 1500 | 0.190 |
Why?
|
| Thionucleosides | 1 | 2021 | 15 | 0.190 |
Why?
|
| Cochlea | 2 | 2023 | 117 | 0.190 |
Why?
|
| Ependymoma | 1 | 2024 | 264 | 0.190 |
Why?
|
| Deoxyadenosines | 1 | 2021 | 43 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 3 | 2016 | 5759 | 0.190 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2021 | 51 | 0.190 |
Why?
|
| DNA Modification Methylases | 2 | 2021 | 176 | 0.190 |
Why?
|
| Image Enhancement | 2 | 2018 | 553 | 0.180 |
Why?
|
| Adolescent | 14 | 2024 | 32784 | 0.180 |
Why?
|
| Supratentorial Neoplasms | 2 | 2012 | 77 | 0.180 |
Why?
|
| Taste Disorders | 1 | 2020 | 17 | 0.180 |
Why?
|
| Radiotherapy | 3 | 2019 | 1858 | 0.180 |
Why?
|
| Hair Follicle | 2 | 2017 | 69 | 0.180 |
Why?
|
| Glutarates | 1 | 2020 | 42 | 0.180 |
Why?
|
| Olfaction Disorders | 1 | 2020 | 31 | 0.180 |
Why?
|
| Drug Synergism | 2 | 2017 | 1355 | 0.180 |
Why?
|
| Ki-67 Antigen | 2 | 2015 | 675 | 0.180 |
Why?
|
| DNA Repair Enzymes | 2 | 2021 | 238 | 0.170 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 1197 | 0.170 |
Why?
|
| Oxidative Phosphorylation | 2 | 2019 | 271 | 0.170 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 1123 | 0.170 |
Why?
|
| Pyrroles | 2 | 2015 | 588 | 0.170 |
Why?
|
| Metabolomics | 2 | 2021 | 503 | 0.170 |
Why?
|
| Hindlimb | 1 | 2000 | 107 | 0.170 |
Why?
|
| Carcinogenesis | 2 | 2017 | 1034 | 0.170 |
Why?
|
| Tumor Hypoxia | 1 | 2019 | 25 | 0.170 |
Why?
|
| Extracellular Space | 1 | 2000 | 135 | 0.170 |
Why?
|
| Sciatic Nerve | 1 | 2000 | 120 | 0.170 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 7320 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 9044 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2011 | 121 | 0.170 |
Why?
|
| 5'-Nucleotidase | 1 | 2019 | 63 | 0.170 |
Why?
|
| Histones | 2 | 2024 | 1512 | 0.170 |
Why?
|
| Protons | 3 | 2021 | 480 | 0.170 |
Why?
|
| Electron Transport Complex I | 1 | 2019 | 67 | 0.170 |
Why?
|
| Oxadiazoles | 1 | 2019 | 60 | 0.170 |
Why?
|
| Viral Matrix Proteins | 1 | 2020 | 179 | 0.160 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2021 | 2178 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2023 | 2272 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 1523 | 0.160 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 536 | 0.160 |
Why?
|
| Mefloquine | 1 | 2018 | 10 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2020 | 155 | 0.160 |
Why?
|
| Circulating Tumor DNA | 1 | 2022 | 275 | 0.160 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2019 | 84 | 0.160 |
Why?
|
| Lymphopenia | 1 | 2021 | 211 | 0.160 |
Why?
|
| Memantine | 1 | 2018 | 50 | 0.160 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2018 | 72 | 0.150 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2021 | 521 | 0.150 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 31079 | 0.150 |
Why?
|
| Molecular Sequence Annotation | 1 | 2019 | 196 | 0.150 |
Why?
|
| Microglia | 1 | 2020 | 181 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2019 | 1032 | 0.150 |
Why?
|
| Universities | 1 | 2019 | 161 | 0.150 |
Why?
|
| Cell Movement | 4 | 2009 | 2468 | 0.150 |
Why?
|
| DNA Methylation | 4 | 2018 | 2770 | 0.150 |
Why?
|
| Culture Media, Serum-Free | 1 | 2017 | 79 | 0.150 |
Why?
|
| Phosphofructokinase-1, Type C | 1 | 2017 | 21 | 0.150 |
Why?
|
| Phthalazines | 1 | 2019 | 262 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 606 | 0.150 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 5143 | 0.150 |
Why?
|
| Peripheral Nervous System | 1 | 1997 | 51 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 6191 | 0.140 |
Why?
|
| Oncologists | 1 | 2019 | 136 | 0.140 |
Why?
|
| Morpholines | 1 | 2019 | 296 | 0.140 |
Why?
|
| Endothelial Cells | 1 | 2023 | 1032 | 0.140 |
Why?
|
| Dasatinib | 3 | 2010 | 881 | 0.140 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2008 | 163 | 0.140 |
Why?
|
| Proton Therapy | 2 | 2021 | 1637 | 0.140 |
Why?
|
| Receptors, Opioid, mu | 1 | 1997 | 96 | 0.140 |
Why?
|
| Insurance, Health | 1 | 2019 | 262 | 0.140 |
Why?
|
| Gene Fusion | 1 | 2018 | 214 | 0.140 |
Why?
|
| Gene Amplification | 1 | 2019 | 765 | 0.140 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 16238 | 0.140 |
Why?
|
| Terminal Care | 1 | 2021 | 466 | 0.140 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 1190 | 0.140 |
Why?
|
| Radiation Tolerance | 1 | 2020 | 639 | 0.140 |
Why?
|
| Attitude to Health | 1 | 2019 | 435 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 3587 | 0.140 |
Why?
|
| ErbB Receptors | 3 | 2019 | 2375 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 5056 | 0.130 |
Why?
|
| Fibronectins | 2 | 2014 | 202 | 0.130 |
Why?
|
| Prospective Studies | 5 | 2023 | 13445 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 495 | 0.130 |
Why?
|
| Pyrazoles | 3 | 2014 | 1551 | 0.130 |
Why?
|
| Aftercare | 1 | 2017 | 251 | 0.130 |
Why?
|
| Homozygote | 3 | 2023 | 772 | 0.130 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 26 | 0.130 |
Why?
|
| Receptor, TIE-2 | 1 | 2016 | 78 | 0.130 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 195 | 0.130 |
Why?
|
| Microarray Analysis | 2 | 2008 | 396 | 0.130 |
Why?
|
| Carboplatin | 3 | 2024 | 880 | 0.130 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 3953 | 0.120 |
Why?
|
| DNA Mismatch Repair | 1 | 2017 | 283 | 0.120 |
Why?
|
| Sequence Deletion | 3 | 2023 | 908 | 0.120 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2015 | 33 | 0.120 |
Why?
|
| Betacoronavirus | 1 | 2020 | 516 | 0.120 |
Why?
|
| Cellular Senescence | 1 | 2017 | 389 | 0.120 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2015 | 165 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2020 | 417 | 0.120 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 339 | 0.120 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 562 | 0.120 |
Why?
|
| Astrocytes | 1 | 2018 | 406 | 0.120 |
Why?
|
| Metformin | 1 | 2018 | 397 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2018 | 727 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 1270 | 0.120 |
Why?
|
| Flow Cytometry | 2 | 2012 | 3042 | 0.120 |
Why?
|
| Biomarkers | 4 | 2015 | 5054 | 0.120 |
Why?
|
| DNA, Neoplasm | 2 | 2022 | 1958 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 738 | 0.110 |
Why?
|
| Neuralgia | 1 | 1997 | 265 | 0.110 |
Why?
|
| Piperidines | 1 | 2019 | 1099 | 0.110 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2013 | 47 | 0.110 |
Why?
|
| Spinal Cord | 1 | 1997 | 718 | 0.110 |
Why?
|
| Heterografts | 1 | 2016 | 738 | 0.110 |
Why?
|
| Comorbidity | 1 | 2020 | 2394 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2019 | 933 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2021 | 1900 | 0.110 |
Why?
|
| Neutrophil Infiltration | 1 | 2013 | 105 | 0.110 |
Why?
|
| Salvage Therapy | 2 | 2013 | 2124 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1072 | 0.110 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2017 | 510 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2019 | 1150 | 0.110 |
Why?
|
| Drug Antagonism | 1 | 2013 | 33 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 883 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 1536 | 0.110 |
Why?
|
| Angiogenic Proteins | 1 | 2013 | 39 | 0.100 |
Why?
|
| Nestin | 1 | 2012 | 42 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2016 | 426 | 0.100 |
Why?
|
| Enzyme Activation | 4 | 2019 | 1801 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2020 | 745 | 0.100 |
Why?
|
| Intermediate Filament Proteins | 1 | 2012 | 80 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2015 | 437 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1658 | 0.100 |
Why?
|
| Microdialysis | 2 | 2004 | 70 | 0.100 |
Why?
|
| Craniospinal Irradiation | 1 | 2013 | 132 | 0.100 |
Why?
|
| Risk Factors | 4 | 2020 | 17911 | 0.100 |
Why?
|
| Decision Making | 1 | 2019 | 1253 | 0.100 |
Why?
|
| Cell Survival | 2 | 2016 | 3058 | 0.100 |
Why?
|
| Stroke | 1 | 2020 | 1061 | 0.100 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 236 | 0.100 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 1761 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 15282 | 0.100 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 757 | 0.100 |
Why?
|
| Phenotype | 2 | 2013 | 6503 | 0.100 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2010 | 258 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 1135 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2024 | 2433 | 0.090 |
Why?
|
| Vincristine | 1 | 2015 | 1582 | 0.090 |
Why?
|
| Retinoblastoma | 1 | 2012 | 189 | 0.090 |
Why?
|
| Biological Assay | 1 | 2012 | 176 | 0.090 |
Why?
|
| Melanoma | 2 | 2020 | 5597 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1614 | 0.090 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2011 | 105 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 1104 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2012 | 572 | 0.090 |
Why?
|
| Piperazines | 1 | 2019 | 2145 | 0.090 |
Why?
|
| Genome, Human | 1 | 2019 | 1896 | 0.090 |
Why?
|
| Mesoderm | 1 | 2012 | 391 | 0.090 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2010 | 99 | 0.090 |
Why?
|
| North America | 1 | 2011 | 341 | 0.090 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2011 | 624 | 0.090 |
Why?
|
| Epigenesis, Genetic | 2 | 2023 | 1440 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 3204 | 0.090 |
Why?
|
| Genetic Testing | 2 | 2017 | 1692 | 0.090 |
Why?
|
| Radiosurgery | 1 | 2019 | 1384 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 2051 | 0.090 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2009 | 18 | 0.080 |
Why?
|
| Chemokine CXCL9 | 1 | 2009 | 24 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 1417 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 2010 | 167 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2010 | 86 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2017 | 804 | 0.080 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 2028 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2017 | 2163 | 0.080 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2009 | 57 | 0.080 |
Why?
|
| B7-H1 Antigen | 1 | 2016 | 1089 | 0.080 |
Why?
|
| Neutropenia | 1 | 2013 | 1005 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 5102 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2014 | 1306 | 0.080 |
Why?
|
| Confusion | 1 | 2008 | 23 | 0.080 |
Why?
|
| Amino Acids | 2 | 2024 | 746 | 0.080 |
Why?
|
| Carcinogenicity Tests | 1 | 2008 | 69 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 14020 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 5238 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 1456 | 0.080 |
Why?
|
| RNA, Double-Stranded | 1 | 2008 | 106 | 0.080 |
Why?
|
| Patient Care | 1 | 2009 | 148 | 0.070 |
Why?
|
| G1 Phase | 1 | 2009 | 305 | 0.070 |
Why?
|
| Texas | 1 | 2019 | 6452 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2007 | 622 | 0.070 |
Why?
|
| SEER Program | 1 | 2012 | 1052 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2014 | 1942 | 0.070 |
Why?
|
| Monocytes | 1 | 2011 | 784 | 0.070 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 590 | 0.070 |
Why?
|
| Tumor Burden | 3 | 2018 | 2033 | 0.070 |
Why?
|
| Risk | 2 | 2023 | 1937 | 0.070 |
Why?
|
| Genotype | 1 | 2015 | 4249 | 0.070 |
Why?
|
| Indoles | 1 | 2012 | 1029 | 0.070 |
Why?
|
| Child | 7 | 2024 | 30596 | 0.070 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 398 | 0.070 |
Why?
|
| Time Factors | 3 | 2019 | 12991 | 0.070 |
Why?
|
| Leiomyosarcoma | 1 | 2008 | 253 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2017 | 4105 | 0.070 |
Why?
|
| Radiography | 1 | 2011 | 1993 | 0.070 |
Why?
|
| Neurons | 1 | 2017 | 2446 | 0.070 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 1173 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 7054 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2008 | 1023 | 0.060 |
Why?
|
| Tetrazoles | 1 | 2006 | 96 | 0.060 |
Why?
|
| Collagen | 1 | 2008 | 723 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2015 | 6343 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2008 | 2087 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2024 | 1929 | 0.060 |
Why?
|
| Annexin A5 | 1 | 2005 | 74 | 0.060 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2007 | 347 | 0.060 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2006 | 127 | 0.060 |
Why?
|
| Glycolysis | 2 | 2018 | 528 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 3657 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 1582 | 0.060 |
Why?
|
| Multiple Chronic Conditions | 1 | 2024 | 17 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2018 | 585 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2023 | 1320 | 0.060 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 576 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2005 | 460 | 0.060 |
Why?
|
| Photons | 2 | 2021 | 536 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2000 | 2142 | 0.060 |
Why?
|
| Transfection | 1 | 2008 | 3110 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 322 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2024 | 17095 | 0.050 |
Why?
|
| Biological Transport | 1 | 2024 | 630 | 0.050 |
Why?
|
| Internal Medicine | 1 | 2024 | 160 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2015 | 920 | 0.050 |
Why?
|
| Celecoxib | 2 | 2014 | 198 | 0.050 |
Why?
|
| Caspases | 1 | 2005 | 672 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 1699 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 2 | 2018 | 1329 | 0.050 |
Why?
|
| Phosphorylation | 4 | 2017 | 4906 | 0.050 |
Why?
|
| Methionine Adenosyltransferase | 1 | 2021 | 9 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 2198 | 0.050 |
Why?
|
| Poly ADP Ribosylation | 1 | 2021 | 9 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2022 | 165 | 0.050 |
Why?
|
| Pyridones | 1 | 2024 | 364 | 0.050 |
Why?
|
| Frozen Sections | 1 | 2021 | 114 | 0.050 |
Why?
|
| Epithelium | 1 | 2023 | 786 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2021 | 254 | 0.050 |
Why?
|
| Gluconates | 1 | 2020 | 10 | 0.050 |
Why?
|
| Phosphogluconate Dehydrogenase | 1 | 2020 | 9 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2021 | 219 | 0.050 |
Why?
|
| Guanine | 1 | 2021 | 157 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 2348 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2011 | 2923 | 0.040 |
Why?
|
| Ultrasonic Waves | 1 | 2020 | 8 | 0.040 |
Why?
|
| Organoids | 1 | 2023 | 329 | 0.040 |
Why?
|
| Capsaicin | 1 | 2000 | 50 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2000 | 203 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 323 | 0.040 |
Why?
|
| Rats | 2 | 2000 | 6404 | 0.040 |
Why?
|
| Leukapheresis | 1 | 2020 | 166 | 0.040 |
Why?
|
| Radiologists | 1 | 2022 | 179 | 0.040 |
Why?
|
| Consensus | 1 | 2024 | 1112 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2005 | 1492 | 0.040 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2021 | 220 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2019 | 155 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2019 | 284 | 0.040 |
Why?
|
| Carbon Isotopes | 1 | 2020 | 362 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2021 | 4020 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 5165 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 233 | 0.040 |
Why?
|
| Nitroimidazoles | 1 | 2019 | 107 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2019 | 220 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 383 | 0.040 |
Why?
|
| Awareness | 1 | 2019 | 115 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 316 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2000 | 455 | 0.040 |
Why?
|
| X-linked Nuclear Protein | 1 | 2018 | 59 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2015 | 2364 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 352 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 2018 | 84 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2019 | 354 | 0.040 |
Why?
|
| Educational Status | 1 | 2019 | 391 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 460 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 354 | 0.040 |
Why?
|
| Travel | 1 | 2019 | 203 | 0.040 |
Why?
|
| Axotomy | 1 | 1997 | 17 | 0.040 |
Why?
|
| Nucleotides | 1 | 2018 | 174 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2015 | 1336 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2009 | 1452 | 0.040 |
Why?
|
| Annual Reports as Topic | 1 | 2017 | 4 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 496 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2008 | 2325 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2018 | 310 | 0.030 |
Why?
|
| Magnetics | 1 | 2016 | 98 | 0.030 |
Why?
|
| DNA Repair | 1 | 2024 | 1906 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2017 | 122 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 666 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2017 | 626 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 562 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 2428 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 493 | 0.030 |
Why?
|
| Oxygen | 1 | 2019 | 789 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2018 | 699 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 2067 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 2169 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2016 | 687 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2016 | 814 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2018 | 7273 | 0.030 |
Why?
|
| Serine | 2 | 2006 | 389 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 2403 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 986 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 1409 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2014 | 104 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 3533 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 1459 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 1341 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 881 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 108 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 1101 | 0.030 |
Why?
|
| Graft Survival | 1 | 2016 | 1083 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 632 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 1143 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2018 | 988 | 0.030 |
Why?
|
| Medical Records | 1 | 2013 | 442 | 0.030 |
Why?
|
| Sample Size | 1 | 2012 | 213 | 0.020 |
Why?
|
| Marital Status | 1 | 2012 | 92 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 1581 | 0.020 |
Why?
|
| Bias | 1 | 2012 | 216 | 0.020 |
Why?
|
| Disease Management | 1 | 2017 | 1092 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2016 | 584 | 0.020 |
Why?
|
| United States | 2 | 2021 | 15891 | 0.020 |
Why?
|
| Esophagitis | 1 | 2013 | 210 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 1606 | 0.020 |
Why?
|
| CpG Islands | 1 | 2014 | 669 | 0.020 |
Why?
|
| Spine | 1 | 2013 | 311 | 0.020 |
Why?
|
| Mitochondria | 1 | 2018 | 1292 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 1692 | 0.020 |
Why?
|
| Vomiting | 1 | 2013 | 361 | 0.020 |
Why?
|
| Nausea | 1 | 2013 | 539 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2313 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 1260 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 483 | 0.020 |
Why?
|
| Transcriptome | 1 | 2018 | 1960 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2024 | 5416 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 1557 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 2346 | 0.020 |
Why?
|
| Weight Loss | 1 | 2013 | 628 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 3904 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 1344 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2013 | 1572 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 360 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 2261 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 4642 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1576 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 2186 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2007 | 233 | 0.020 |
Why?
|
| Vitronectin | 1 | 2005 | 24 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2006 | 158 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2006 | 132 | 0.020 |
Why?
|
| Threonine | 1 | 2005 | 163 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2006 | 153 | 0.020 |
Why?
|
| G2 Phase | 1 | 2005 | 218 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 6780 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 1053 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 439 | 0.010 |
Why?
|
| Incidence | 1 | 2014 | 5841 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 617 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2013 | 2458 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 1469 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 497 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 2657 | 0.010 |
Why?
|
| Pregnancy | 1 | 2014 | 8131 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 1942 | 0.010 |
Why?
|